Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
19.7
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Contents of this document
Financial Results PresentationFY2026 second quarter8 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥11,672 hundred million+19.7%
Operating profit¥1,938 hundred million+34.4%
Net income¥1,515 hundred million+15.8%
Selling, general and administrative expenses¥4,661 hundred million
Results for the three months of the current quarterStandalone global product sales for FY2026 Q2: Enhertu, ¥464.5 billion; Datroway, ¥48.3 billion. Consolidated income statement figures are presented on a cumulative second-quarter basis.
Full-year earnings forecast
Revenue
¥23,400 hundred million
Cost of sales
¥5,500 hundred million
Loss compensation to the CMO
¥800 hundred million
Selling, general and administrative expenses
¥9,300 hundred million
R&D expenses
¥5,000 hundred million
Core operating profit
¥3,600 hundred million
Non-core expenses
¥400 hundred million
Operating profit
¥3,200 hundred million
Pretax profit
¥3,340 hundred million
Profit for the year attributable to owners of the parent
¥2,510 hundred million
Enhertu product sales
¥9,153 hundred million
Datroway product sales
¥1,189 hundred million
Progress against full-year forecast 通期の予想に対して、いまどこまで進んだかの割合です。
Enhertu product sales51.9%
Datroway product sales41.4%
What the company explained in this material
Self-assessment against the planThe company's self-assessment against its own plan.
Progressing steadily toward achieving record-high full-year revenue and substantial year-on-year profit growthBreakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Revenue
Foreign Exchange Effects
¥739 hundred million
Oncology Business Unit
¥1,143 hundred million
American Regent Unit
¥254 hundred million
EU Specialty Business Unit
¥8 hundred million
ASCA Business Unit
¥115 hundred million
Upfront payments, milestones, etc.
¥266 hundred million
Operating profit
Revenue
¥1,919 hundred million
Cost of sales
¥11 hundred million
Selling, general and administrative expenses
¥969 hundred million
R&D expenses
¥232 hundred million
Non-core income and expenses
¥210 hundred million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/yen
159.37 Yen
EUR/yen
184.35 Yen
New initiatives
- Partnership with Summit Therapeutics for the joint development and commercialization of Datroway plus ivonescimab
- Establishment of a Commercialization Unit in April 2027
- External cost optimization through Operational Excellence, AI-driven business process transformation, and structural reform
Key KPIsA metric the company considers important as a management benchmark.
- Enhertu global product sales¥4,645 hundred millionYear on year against the same period last year+45.9%
- Datroway global product sales¥483 hundred millionYear on year against the same period last year+207.2%
- Cumulative number of patients prescribed Datroway9,800 students
- Progress toward the full-year forecast for Enhertu product sales51.9 %
- Progress toward the full-year forecast for Datroway product sales41.4 %
Segment results
Japan Business
Sales
¥2,327 hundred million
Year on year against the same period last year-6.9%
Daiichi Sankyo Healthcare
Sales
¥483 hundred million
Year on year against the same period last year+5.2%
Oncology Business
Sales
¥4,226 hundred million
Year on year against the same period last year+54.8%
American Regent
Sales
¥779 hundred million
Year on year against the same period last year-19.5%
EU Specialty Business
Sales
¥1,492 hundred million
Year on year against the same period last year+9.1%
ASCA (Asia and Latin America) Business
Sales
¥1,425 hundred million
Year on year against the same period last year+20.9%
Medium-term management plan targets
Operational Excellence
TargetGenerate total optimization benefits of at least ¥200 billion over 5 years
Target fiscal yearThe 5-year period for achieving the Sixth Medium-Term Business Plan
Oncology
TargetGlobal top 5
Target fiscal yearFY2030
Risk amount incorporated into the outlookThe amount representing the range of variation the company expects in its forecast.
Loss compensation to the CMO
¥800 hundred million
DetailsRecognition of a provision for loss compensation related to the minimum purchase obligation for CY2028
| Item | Details |
|---|---|
| Document type | Financial Results Presentation |
| Fiscal Period Covered | FY2026 second quarter |
| Net Sales | ¥11,672 hundred million (YoY +19.7%) |
| Operating profit | ¥1,938 hundred million (YoY +34.4%) |
| Net income | ¥1,515 hundred million (YoY +15.8%) |
| Selling, general and administrative expenses | ¥4,661 hundred million |
| Results for the three months of the current quarter | Standalone global product sales for FY2026 Q2: Enhertu, ¥464.5 billion; Datroway, ¥48.3 billion. Consolidated income statement figures are presented on a cumulative second-quarter basis. |
| Full-year earnings forecast | Revenue ¥23,400 hundred million / Cost of sales ¥5,500 hundred million / Loss compensation to the CMO ¥800 hundred million / Selling, general and administrative expenses ¥9,300 hundred million / R&D expenses ¥5,000 hundred million / Core operating profit ¥3,600 hundred million / Non-core expenses ¥400 hundred million / Operating profit ¥3,200 hundred million / Pretax profit ¥3,340 hundred million / Profit for the year attributable to owners of the parent ¥2,510 hundred million / Enhertu product sales ¥9,153 hundred million / Datroway product sales ¥1,189 hundred million |
| Progress against full-year forecast | Enhertu product sales 51.9% / Datroway product sales 41.4% |
| Self-assessment against the plan | Progressing steadily toward achieving record-high full-year revenue and substantial year-on-year profit growth |
| Segment results | Japan Business Sales ¥2,327 hundred million / yoy_pct -6.9 / Daiichi Sankyo Healthcare Sales ¥483 hundred million / yoy_pct 5.2 / Oncology Business Sales ¥4,226 hundred million / yoy_pct 54.8 / American Regent Sales ¥779 hundred million / yoy_pct -19.5 / EU Specialty Business Sales ¥1,492 hundred million / yoy_pct 9.1 / ASCA (Asia and Latin America) Business Sales ¥1,425 hundred million / yoy_pct 20.9 |
| Breakdown of Factors Affecting the Change | Revenue Foreign Exchange Effects ¥739 hundred million / Oncology Business Unit ¥1,143 hundred million / American Regent Unit ¥254 hundred million / EU Specialty Business Unit ¥8 hundred million / ASCA Business Unit ¥115 hundred million / Upfront payments, milestones, etc. ¥266 hundred million / Operating profit Revenue ¥1,919 hundred million / Cost of sales ¥11 hundred million / Selling, general and administrative expenses ¥969 hundred million / R&D expenses ¥232 hundred million / Non-core income and expenses ¥210 hundred million |
| Key KPIs | Indicator name Enhertu global product sales / Value ¥4,645 hundred million / Year on year against the same period last year +45.9%, Indicator name Datroway global product sales / Value ¥483 hundred million / Year on year against the same period last year +207.2%, Indicator name Cumulative number of patients prescribed Datroway / Value 9,800 students / Year on year against the same period last year Not disclosed, Indicator name Progress toward the full-year forecast for Enhertu product sales / Value 51.9 % / Year on year against the same period last year Not disclosed, Indicator name Progress toward the full-year forecast for Datroway product sales / Value 41.4 % / Year on year against the same period last year Not disclosed |
| Assumptions Underlying the Business Outlook | USD/yen 159.37 Yen / EUR/yen 184.35 Yen |
| Risk amount incorporated into the outlook | Loss compensation to the CMO ¥800 hundred million |
| Medium-term management plan targets | Operational Excellence Target Generate total optimization benefits of at least ¥200 billion over 5 years / Target fiscal year The 5-year period for achieving the Sixth Medium-Term Business Plan / Oncology Target Global top 5 / Target fiscal year FY2030 |
| New initiatives | Partnership with Summit Therapeutics for the joint development and commercialization of Datroway plus ivonescimab, Establishment of a Commercialization Unit in April 2027, External cost optimization through Operational Excellence, AI-driven business process transformation, and structural reform |
Items this document does not state (14)
Ordinary incomeGross Profit MarginOperating profit marginUnit price and quantity metricsNumber of stores and locationsNumber of employeesFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Driven by strong growth in core products, including Enhertu and Datroway, the favorable impact of the weaker yen, increased revenue, and an improved cost ratio.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.